Hematology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Search results for "CTL019"

Eight of 14 patients in the first trial of the University of Pennsylvania’s personalized cellular therapy for chronic lymphocytic leukemia ( CLL ) responded to the therapy, with some complete remissio ...

Ninety-three percent of pediatric patients ( 55 of 59 ) with relapsed/refractory acute lymphoblastic leukemia ( ALL ) went into remission after receiving an investigational therapy made from their own ...

The European Commission ( EC ) has approved Kymriah ( Tisagenlecleucel, formerly CTL019 ). The approved indications are for the treatment of pediatric and young adult patients up to 25 years of age wi ...